Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 35 条
  • [1] Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials
    Núria Buil-Bruna
    María Jesús Garrido
    Marion Dehez
    Amandine Manon
    Thi Xuan Quyen Nguyen
    Edda L. Gomez-Panzani
    Iñaki F. Trocóniz
    Clinical Pharmacokinetics, 2016, 55 : 461 - 473
  • [2] Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study
    Prasad, V
    Thanh, Truong X. M.
    Houchard, A.
    Bodei, L.
    NEUROENDOCRINOLOGY, 2017, 105 : 253 - 253
  • [3] Lanreotide Autogel/ Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
    Reidy-Lagunes, D.
    Kulke, M. H.
    Wolin, E. M.
    Singh, S.
    Ferone, D.
    Hoersch, D.
    Mirakhur, B.
    Hoffmanns, P.
    Houchard, A.
    Caplin, M.
    Baudin, E.
    NEUROENDOCRINOLOGY, 2017, 105 : 209 - 209
  • [4] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Thanh, Truong X. M.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2019, 108 : 157 - 157
  • [5] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/ Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Majdi, A.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 204 - 204
  • [6] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
    Adelman, Daphne T.
    Van Genechten, Dirk
    Megret, Clementine M.
    Thanh, Xuan-Mai T. Truong
    Hand, Philippa
    Martin, Wendy A.
    ADVANCES IN THERAPY, 2019, 36 (12) : 3409 - 3423
  • [7] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
    Daphne T. Adelman
    Dirk Van Genechten
    Clémentine M. Megret
    Xuan-Mai T. Truong Thanh
    Philippa Hand
    Wendy A. Martin
    Advances in Therapy, 2019, 36 : 3409 - 3423
  • [8] Long-Term Efficacy and Safety with Lanreotide Autogel/ Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
    Phan, A. T.
    Pavel, M.
    Caplin, M.
    Wolin, E. M.
    Mirakhur, B.
    Massien, C.
    Liyanage, N.
    Lowenthal, Pittman S.
    Ruszniewski, P.
    NEUROENDOCRINOLOGY, 2017, 105 : 207 - 207
  • [9] Exploratory Assessment of the Clinical Value of Baseline (BL) Circulating Tumour Cells (CTC) to Predict Symptomatic Response in Pts with Functioning Midgut Neuroendocrine Tumours (NETs) Receiving Lanreotide Autogel (LAN): CALM-NET Study Results.
    Meyer, T.
    Khan, M.
    Toumpanakis, C.
    Shetty, S.
    Houchard, A.
    Goyal, A.
    Shah, T.
    NEUROENDOCRINOLOGY, 2019, 108 : 131 - 131
  • [10] CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)
    Meyer, T.
    Higgs, K.
    Hickling, M.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 33 - 33
1234